27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...
MPR2d
Amvuttra Gains Approval for Transthyretin Amyloid Cardiomyopathy
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
Alnylam initiated with a Buy at Redburn Atlantic
Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...
Alnylam announces FDA approval of Qfitlia for treatment of hemophilia A or B
Pharmaceuticals highlighted the significance of the FDA approval of Qfitlia, the sixth Alnylam-discovered RNAi therapeutic ...